Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI)

Gunnar Weise; Christina Rautenberg; Alexander Denk; Radwan Massoud; Elisabeth Meedt; Daniel Wolff; Thomas Schroeder; Francis Ayuk

PMC · DOI:10.1038/s41409-025-02778-w·December 16, 2025

Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI)

Gunnar Weise, Christina Rautenberg, Alexander Denk, Radwan Massoud, Elisabeth Meedt, Daniel Wolff, Thomas Schroeder, Francis Ayuk

PDF

Open Access

Abstract

Linked entities

Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.

Genes2

CRP ALB

Proteins2

Species1

Homo sapiens(human · species)

Chemicals1

creatinine

Diseases9

Multiple Myeloma malignancy AML hematologic malignancies MDS myelodysplastic syndrome and myeloproliferative neoplasms NRM ALL lymphomas

Figures1

Click any figure to enlarge with its caption.

Peer Reviews

No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.

Videos

No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.

Taxonomy

TopicsAcute Myeloid Leukemia Research · Inflammatory Biomarkers in Disease Prognosis · Hematopoietic Stem Cell Transplantation